Lexicon’s next act: betting big on first-in-class cardiometabolic medicine
“We’re really on the precipice of moving the company into that next stage of maturity,” Dr. Mike Exton
Company: Lexicon Pharmaceuticals
2 stories
Make us preferred on GoogleLatest stories
Page 1 of 1
New CEO Dr. Mike Exton has big plans for Lexicon Pharma in 2025
Lexicon has been discovering new genetic science since the Human Genome Project. Dr. Mike Exton, with over 2 decades of pharma experience, was drafted in this summer and has plans to make history.
